Pharma's Almanac TV
PA TV
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Facility
50 Articles Available
1
3
Can't find what you're looking for? Try our
advanced search
.
Pharma Equipment
PHARMA FACILITY OPPORTUNITY ALERT: Pharmaceutical Grade Facility Available For Sale Or Lease
PR-M03-20-NI-034
Engineering
Integrated Design and Engineering: Focused on the End Goal
PAO-M03-20-CL-001
Facility
WuXi Biologics Completes Weather-Tight Seal of its Biologics Manufacturing Facility in Ireland
PR-M03-20-NI-019
API Manufacturing
Piramal Pharma Solutions Invests $25 Million CAD to Expand its Aurora, Canada Facility with a State-of-the-Art API Manufacturing Wing
PR-M01-20-NI-038
Cell and Gene Therapy
The Center for Breakthrough Medicines to Build a Cell and Gene Therapy CDMO in King of Prussia, PA
PR-M01-20-NI-035
Investment
Governor Cooper Announces Over 460 Jobs in Durham as Eli Lilly and Company Selects North Carolina for Major Pharmaceutical Plant
PR-M01-20-NI-034
Expansion
UCB to Build New Biotech Manufacturing Plant in Belgium
PR-M01-20-NI-004
Liposome Formulations
FUJIFILM Toyama Chemical Announces Completion of Japan’s First Manufacturing Facility for Commercial Liposome Formulations
PR-M12-19-NI-015
Facility
Amgen Selects Location for R&D Facility in ihe South San Francisco Biotechnology Hub
PR-M12-19-NI-014
R&D Facility
Horizon Therapeutics plc Opens New Manufacturing and R&D Facility in South San Francisco
PR-M12-19-NI-008
Facility
HALIX Celebrates Grand Opening of its State-of-the-Art cGMP Facility
PR-M11-19-NI-036
Facility Design Trends
New Trends in Tech Impacting Pharma Facility Design and Construction
PAP-Q3-19-CL-009
Expansion
TriPharm Services Announces Creation of Pharmaceutical Manufacturing Center
PR-M10-19-NI-028
Opening
GENEWIZ Celebrates Opening of European Headquarters in Germany
PR-M09-19-NI-052
Investment
GSK Invests $120 million in Next-generation US Biopharmaceutical Manufacturing Facility
R-M09-19-NI-051
Expansion
NeoGenomics Announces Grand Opening of New Pharma Services Laboratory in Singapore
PR-M08-19-NI-022
Capacity Expansion
GenScript Biotech's Biologics R&D and Production Center is Formally Put Into Operation
PR-M07-19-NI-075
Acquisition
Lonza Will Purchase a Sterile Fill-Finish Site from Novartis
PAO-M07-19-NI-012
Water for Injection
Membrane-Based Reverse Osmosis Systems for WFI Production
PAO-NI-0719-CL-001
M&A
FLAMMA Acquires Teva’s Philadelphia cGMP Facility Marking Entry into the US Marketplace with Labs & Pilot Plant
PR-M07-19-NI-013
Capacity Expansion
Cambrex Adds New Lab Space
PAO-M06-19-NI-009
Capacity Expansion
Seqens to Unveil New Innovation and Development Center of Excellence
PR-M06-19-NI-019
New Facility
Iovance Biotherapeutics Announces New Facility to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products
PR-M05-19-NI-082
Lean Delivery
Reducing Waste with Lean Delivery in Facility Design and Construction
PAP-Q2-2019-CL-013
1
3
»
